IVVD - NASDAQ
Invivyd, Inc.
$1.10
-1.3%Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
At a Glance
Live SnapshotInvivyd, Inc. Management Team
Mr. Timothy Lee
Chief Commercial Officer
Compensation
$553,865
Mr. William E. Duke Jr., M.B.A.
Chief Financial Officer, Principal Accounting Officer & Principal Executive Officer
Compensation
$635,543
Ms. Julie Green M.B.A.
Chief Human Resources Officer & Head of Communications
Compensation
$542,353
Ms. Jill Andersen J.D.
Chief Legal Officer & Corporate Secretary
Compensation
$931,680
Dr. Robert D. Allen Ph.D.
Chief Scientific Officer
Compensation
$828,180
Dr. Mark A. Wingertzahn Ph.D.
Senior Vice President of Clinical Development & Medical Affairs
Scott Young
Senior Vice President of Investor Relations & Corporate Communications
Invivyd, Inc. Insider Positioning
During the last 12 months, insiders have purchased $125K and sold $521K worth of IVVD shares, resulting in $396K of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
227.2K
354.23K
-354K
-$354K
6-9 Months
50.0K
125.00K
0
0.00
+125K
+$125K
9-12 Months
0
0.00
277.7K
166.67K
-167K
-$167K
Top Buyers
Mclaughlin Kevin F
Director
$125K
Top Sellers
Andersen Jill
Officer: Chief Legal Officer, Secretary
$155K
Duke William E.
Officer: Chief Financial Officer
$93K
Lee Timothy Edward
Officer: Chief Commercial Officer
$93K
Green Julie
Officer: Chief Human Resources Officer
$93K
Allen Robert D. Iii
Officer: Chief Scientific Officer
$86K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $396K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
IVVD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 06, 2026 | May 19, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 07, 2025 | May 20, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 18, 2024 | May 21, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 10, 2023 | May 23, 2023 | 2023 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.